Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
Authors:
- 29 May 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 15 (6) , 475-485
Abstract
Introduction: Triantennary N-acetyl galactosamine (GalNAc3) – conjugated antisense oligonucleotides (ASOs) have demonstrated improved hepatocyte uptake and pharmacologic activity over their parent unconjugated ASOs in animals and humans. Areas covered: In this review, the ADME (absorption, distribution, metabolism, and excretion) characteristics of GalNAc3-conjugated ASOs in animals and in humans are summarized, and their clinical relevance is evaluated from the clinical pharmacology perspectives. Expert opinion: ASOs distribute to tissues via receptor-mediated processes, and conjugation to a ligand specific to certain cell types can improve target tissue delivery. GalNAc3-conjugation represents a good example on this regard and has demonstrated ideal characteristics of a prodrug to target delivery of ASOs to hepatocytes via the asialoglycoprotein receptor (ASGPR). The improved potency and safety margin permit more flexible dosing (e.g. monthly or less frequently if needed) taking full advantage of the long half-life of the parent ASO in humans. However, while still speculative, it should be noted that ASGPR-mediated uptake could become nonlinear with dose and factors that impact ASGPR expression or compete with ASGPR-mediated uptake could potentially affect the uptake of GalNAc3-conjugated ASOs, further studies are warranted.Keywords
Funding Information
- paper was not funded
This publication has 73 references indexed in Scilit:
- Prodrugs—from Serendipity to Rational DesignPharmacological Reviews, 2011
- Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cellsNature Communications, 2011
- A New Splice Variant of the Major Subunit of Human Asialoglycoprotein Receptor Encodes a Secreted Form in HepatocytesPLOS ONE, 2010
- Prodrugs: design and clinical applicationsNature Reviews Drug Discovery, 2008
- Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100Drug Metabolism and Disposition, 2007
- Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)Oligonucleotides, 2006
- The Asialoglycoprotein Receptor Mediates Hepatic Binding and Uptake of Natural Hepatitis B Virus Particles Derived From Viraemic CarriersJournal of General Virology, 1994
- Hypothesis: Galactosyl and N‐acetylgalactosaminyl homeostasis: A function for mammalian asialoglycoprotein receptorsBioEssays, 1994
- Hepatic Binding Protein: The Galactose-Specific Receptor of Mammalian HepatocytesHepatology, 1983
- Carbohydrate-Specific Receptors of the LiverAnnual Review of Biochemistry, 1982